Chemical Structure : DH20931
货号: PC-25458Not For Human Use, Lab Use Only.
DH20931 is a first-in-class, potent small-molecule agonist of Ceramide Synthase 2 (CerS2) with activation constant (Kact) of 16.54 nM, exhibits potent, broad-spectrum, and receptor-independent antitumor activity in vitro and in vivo.
大包装,大折扣!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
DH20931 is a first-in-class, potent small-molecule agonist of Ceramide Synthase 2 (CerS2) with activation constant (Kact) of 16.54 nM, exhibits potent, broad-spectrum, and receptor-independent antitumor activity in vitro and in vivo.
DH20931 exhibits the significant growth inhibitory effects on both triple-positive and triple-negative human breast cancer cell lines with IC50 in the range of 0.3-3.9 uM.
DH20931 potently inhibits the viability of wild-type 4T1 cells, but CERS2-knockout cells.
DH20931 exerts its cytotoxic effects by directly activating CerS2 and driving the overproduction of pro-apoptotic VLCCs.
DH20931 inhibits breast cancer growth in vitro and in vivo, independent of hormone receptor status.
DH20931 induces ER stress through the ATF4 pathway in a CerS2-dependent manner.
DH20931 promotes a novel CerS2-IP3R1 interaction, enhances ER-mitochondria proximity, and triggers mitochondrial Ca²⁺ overload.
DH20931 induces robust apoptosis in breast cancer cells in a CerS2-dependent manner.
分子量 | 368.86 | |
分子式 | C21H21ClN2O2 | |
外观性状 | Solid | |
储存条件 |
|
|
Solubility |
10 mM in DMSO |
1. Zajac-Kaye M, et al. bioRxiv [Preprint]. 2025 Aug 21:2025.08.15.670525.
2. Jaiswal AS, et al. Bioorg Med Chem Lett. 2014 Oct 15;24(20):4850-3.
备案号:沪ICP备16042516号-1 Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright